The patients will receive 0.9% saline for intravenous bottle with 100ml looks identical to the antibiotic at the start of anesthetic induction

The patients will receive 2 g of cefazolin diluted in 0.9% saline by endovenous at the start of anesthetic induction

Breast Neoplasms

Breast-Conserving Surgery

Wound Infection

Antibiotic Prophylaxis

2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction

Cefazolin

0.9% saline sterile by endovenous, once, at the moment of anesthetic induction

sterile saline

The patient will be submitted to a conservative oncologic breast surgery

oncologic breast surgery

Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.

Microbiology

Universidade Do Vale Do Sapucai

Antibiotic Prophylaxis in Oncological Surgery of Breast

Antibiotic Prophylaxis in Oncological Surgery of Breast: Randomized Clinical Trial

To evaluate the influence of antibiotic prophylaxis in surgical site infection rates

To evaluate the microbiota that infects the skin in oncological breast surgery

Fabiola Soares Moreira Campos

Department of gynecology

Chemotherapy regimen (XP):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr repeat every 3 weeks

XT Regimen:
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs Repeat every 3 weeks

First Line Chemotherapy

Capecitabine Plus Cisplatin Versus Capecitabine Plus Paclitaxel

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.
Chemotherapy regimen (XP):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks
Chemotherapy regimen (XT):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks

Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)

Samsung Medical Center

Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma

A Randomized Phase II Trial of Capecitabine Plus Cisplatin (XP) Versus Capecitabine Plus Paclitaxel (XT) as a First-line Treatment for Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Young-Hyuck Im

professor

HER-2 positive subjects treated with trastuzumab

HER-2 negative subjects not treated with trastuzumab

Brain and Central Nervous System Tumors

Breast Cancer

Cognitive/Functional Effects

Drug/Agent Toxicity by Tissue/Organ

Psychosocial Effects of Cancer and Its Treatment

Trastuzamab, 6mg/kg, within 48 hrs before BBBD
Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles

trastuzumab

200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion

carboplatin

2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion

methotrexate

STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2

sodium thiosulfate

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients

mannitol/tumore della mammella

Antibiotic Prophylaxis in Oncological Surgery of Breast

Efficacy Comparison Study of Combination Regimens to Treat Advanced Esophageal Squamous Cell Carcinoma

BBBD Followed By Methotrexate and Carboplatin With or Without Trastuzumab in Treating Women With Breast Cancer That Has Spread to the Brain

Il database di erbe medicinali più completo supportato dalla scienza